Hostname: page-component-848d4c4894-5nwft Total loading time: 0 Render date: 2024-06-01T02:59:42.566Z Has data issue: false hasContentIssue false
  • English
  • Français

Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: Results of a multi-centre observational trial

Published online by Cambridge University Press:  16 April 2020

Duerten Kudla ,
Martin Lambert ,
Sabine Domin ,
Siegfried Kasper  and
Dieter Naber
Duerten Kudla*
Affiliation:
Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246Hamburg, Germany
Martin Lambert
Affiliation:
Psychosis Early Detection and Intervention Centre (PEDIC), Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Sabine Domin
Affiliation:
Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246Hamburg, Germany
Siegfried Kasper
Affiliation:
Department of General Psychiatry, Medical University of Vienna, Vienna, Austria
Dieter Naber
Affiliation:
Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246Hamburg, Germany
*
*Corresponding author. Tel.: +49 40 42803 2227; fax: +49 40 42803 2999. E-mail address:kudla@uke.uni-hamburg.de (D. Kudla).
Get access

Abstract

Purpose

The ZEISIG study (Ziprasidone Experience in Schizophrenia in Germany/Austria) investigated the effectiveness of ziprasidone as measured by discontinuation rates and mean changes of the BPRS total. Secondary objectives included quality of life, subjective well-being, tolerability, and safety.

Subjects and methods

Two hundred and seventy-six subjects with schizophrenia and schizoaffective disorder were treated within an open-label, 12-week, prospective, flexible-dose observational trial of ziprasidone (40–160 mg/day). Baseline and outcome assessments mainly included Brief Psychiatric Rating Scale (BPRS), Clinical Global Impressions Scale (CGI), Short-Form 12 (SF-12), and Subjective Well-being under Neuroleptic treatment (SWN-K).

Results

Study discontinuation due to any cause was evident in 58% of subjects, most of them within the first 4 weeks after study initiation. In study completers, ziprasidone was associated with improvements in BPRS total (44.8 to 33.6; p < 0.001), CGI, SF-12, and SWN-K total scores (80.5 to 89.5). Ziprasidone was related to reduction of weight, fasting glucose, and serum lipids. No cardiovascular adverse event or significant increase of the QTc interval was observed.

Discussion and conclusion

Approximately 60% of subjects discontinued ziprasidone prematurely, probably related to an initial and overall underdose. The present study confirmed previous tolerability and safety data of ziprasidone as well as results of its effectiveness. Independent from reason to switch, previous antipsychotic class, and severity of illness at baseline, the recommended starting dose of 80 mg/day as well as the maximum treatment dose of 160 mg/day may not be sufficient for a selected subgroup of patients.

Keywords

SchizophreniaAtypical antipsychoticsZiprasidoneQuality of life
Type
Schizophrenia and Psychotic Disorder
Information
European Psychiatry , Volume 22 , Issue 3 , April 2007 , pp. 195 - 202
Copyright
Copyright © Elsevier Masson SAS 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addington, D.E.Pantelis, C.Dineen, M.Benattia, I.Romano, S.J.Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry 2004;65:1624–1633.10.4088/JCP.v65n1207CrossRefGoogle ScholarPubMed
American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. In: American Psychiatric Association practice guidelines for the treatment of psychiatric disorders. Compendium 2004. second edition. Arlington, VA: APA; 2004. p. 249–440.Google Scholar
Arato, M.O'Connor, R.Meltzer, H.Y.ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002;17:207–215.10.1097/00004850-200209000-00001CrossRefGoogle ScholarPubMed
Bagnall, A.Lewis, R.A.Leitner, M.L.Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2000;4:CD001945.Google Scholar
Brook, S.Walden, J.Benattia, I.Siu, C.O.Romano, S.J.Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology 2005;178:514–523.10.1007/s00213-004-2082-5CrossRefGoogle Scholar
Citrome, L.Volavka, J.Czobor, P.Brook, S.Loebel, A.Mandel, F.S.Efficacy of ziprasidone against hostility in schizophrenia: post hoc analysis of randomized, open-label study data. J Clin Psychiatry 2006;67:638–642.10.4088/JCP.v67n0415CrossRefGoogle ScholarPubMed
Clark, G.American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596–601.Google Scholar
Franciosi, L.P.Kasper, S.Garber, A.J.Johnson, D.L.Krauss, R.M.Marder, S.R.et al.Advancing the treatment of people with mental illness: a call to action in the management of metabolic issues. J Clin Psychiatry 2005;66:790–798.Google Scholar
Guy, W.ECDEU assessment manual for psychopharmacology, revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976. p. 218–222.Google Scholar
Harrigan, E.P.Miceli, J.J.Anziano, R.Watsky, E.Reeves, K.R.Cutler, N.R.et al.A randomized evaluation of the effects of six antipsychotic agents on QTc in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62–69.10.1097/01.jcp.0000104913.75206.62CrossRefGoogle ScholarPubMed
Harvey, P.D.Meltzer, H.Simpson, G.M.Potkin, S.G.Loebel, A.Siu, C.et al.Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 2004;66:101–113.10.1016/j.schres.2003.07.009CrossRefGoogle ScholarPubMed
Harvey, P.D.Bowie, C.R.Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness. Expert Opin Pharmacother 2005;6:337–346.10.1517/14656566.6.2.337CrossRefGoogle ScholarPubMed
Henderson, D.C.Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 2005;66(Suppl 6):11–20.Google ScholarPubMed
Joyce, A.T.Harrison, D.J.Loebel, A.D.Carter, C.T.Ollendorf, D.A.Effect of initial ziprasidone dose on length of therapy in schizophrenia. Schizophr Res 2006;83:285–292.10.1016/j.schres.2006.01.009CrossRefGoogle Scholar
Lambert, M.Conus, P.Schimmelmann, B.Eide, P.Ward, J.Yuen, H.P.et al.Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study. Pharmacopsychiatry 2005;38:206–213.10.1055/s-2005-873155CrossRefGoogle ScholarPubMed
Lambert, M.Eich, F.X.Schacht, M.Naber, D.Linden, M.Schimmelmann, B.G.Remission of severely impaired subjective well-being in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatrica Scand, in press, doi:10.1111/j.1600-0447.2006.00862x.Google Scholar
Levy, W.O.Robichaux-Keene, N.R.Nunez, C.No significant QTc interval changes with high-dose ziprasidone: a case series. J Psychiatr Pract 2004;10:227–232.10.1097/00131746-200407000-00003CrossRefGoogle ScholarPubMed
Lieberman, J.A.Stroup, T.S.McEvoy, J.P.Swartz, M.S.Rosenheck, R.A.Perkins, D.O.et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–1223.10.1056/NEJMoa051688CrossRefGoogle ScholarPubMed
Loebel, A.Siu, C.Romano, S.Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr 2004;9:357–364.10.1017/S1092852900009342CrossRefGoogle ScholarPubMed
McGorry, P.D.Killackey, E.Lambert, T.Lambert, M.Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005;39:1–30.Google Scholar
Mamo, D.Kapur, S.Shammi, C.M.Papatheodorou, G.Mann, S.Therrien, F.et al.A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004;161:818–825.10.1176/appi.ajp.161.5.818CrossRefGoogle ScholarPubMed
Mullins, C.D.Shaya, F.T.Zito, J.M.Obeidat, N.Naradzay, J.Harrison, D.J.Effect of initial ziprasidone dose on treatment persistence in schizophrenia. Schizophr Res 2006;83:277–284.10.1016/j.schres.2006.01.013CrossRefGoogle Scholar
Naber, D.Moritz, S.Lambert, M.Pajonk, F.Holzbach, R.Mass, R.et al.Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50:79–88.10.1016/S0920-9964(00)00166-3CrossRefGoogle ScholarPubMed
Nemeroff, C.B.Lieberman, J.A.Weiden, P.J.Harvey, P.D.Newcomer, J.W.Schatzberg, A.F.et al.From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr 2005;10:1–20.Google ScholarPubMed
Olie, J.P.Spina, E.Murray, S.Yang, R.Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int Clin Psychopharmacol 2006;21:143–151.Google ScholarPubMed
Overall, J.E.Gorham, D.R.BPRS. Brief Psychiatric Rating Scale. In: Guy, W.Bonato, R.R. editors. EDCEU assessment battery. Revised ed.Rockville, MD: EDCEU; 1976. p. 157–169.Google Scholar
Pajonk, F.G.Clinical trial design in schizophrenia: implications for clinical decisions. Curr Opin Psychiatry 2005;18:692–699.10.1097/01.yco.0000186017.72973.8cCrossRefGoogle ScholarPubMed
Simpson, G.M.Angus, J.W.A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11–19.10.1111/j.1600-0447.1970.tb02066.xCrossRefGoogle ScholarPubMed
Simpson, G.M.Glick, I.D.Weiden, P.J.Romano, S.J.Siu, C.O.Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161:1837–1847.10.1176/ajp.161.10.1837CrossRefGoogle ScholarPubMed
Ware, J. Jr.Kosinski, M.Keller, S.D.A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220–233.10.1097/00005650-199603000-00003CrossRefGoogle ScholarPubMed
Weiden, P.J.Simpson, G.M.Potkin, S.G.O'Sullivan, R.L.Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003;64:580–588.10.4088/JCP.v64n0514CrossRefGoogle ScholarPubMed
Wirshing, D.A.Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 2004;65(Suppl 18):13–26.Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.